• FR

ERMETIC

Publications:
  • Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer: the ERMETIC Study Part 3
  • Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for th
  • Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2)
  • Intergroupe Francophone de Cancérologie Thoracique

    Siège social
    10 rue de la Grange-Batelière
    75009 PARIS

    Standard : 01.56.81.10.45
    Recherche Clinique : 01.56.81.10.46

    Informations

    • Mentions légales
    • Avertissement
    • Plan du site

    Suivez-nous

    • Twitter
    • LinkedIn
    © IFCT 2021 - IFCT_TOUS_DROITS_RESERVES
    Contact Devenir membre Espace membre E-lettre Deconnexion